Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphocyte gene therapy.

K W Culver1, W F Anderson, R M Blaese

  • 1National Institutes of Health, Bethesda, MD 20892.

Human Gene Therapy
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Genetically modified T cells show promise for treating adenosine deaminase deficiency. These corrected cells restore enzyme activity and immune function, indicating their potential as a gene therapy approach.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The treatment of adenosine deaminase deficiency.

Immunology today·2014
Same author

A novel approach using transcomplementing adenoviral vectors for gene therapy of adrenocortical cancer.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2002
Same author

Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells.

Biochemical and biophysical research communications·2001
Same author

AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits.

Gene therapy·2001
Same author

Development of a skin-based metabolic sink for phenylalanine by overexpression of phenylalanine hydroxylase and GTP cyclohydrolase in primary human keratinocytes.

Gene therapy·2001
Same author

Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

Blood·2000
Same journal

Evaluation of the Toxicity and Efficacy of an Adeno-Associated Viral Vector Expressing <i>BEST1</i> Delivered by Subretinal Injection in a Canine Model of Human Bestrophinopathy.

Human gene therapy·2026
Same journal

The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach.

Human gene therapy·2026
Same journal

Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives.

Human gene therapy·2026
Same journal

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration.

Human gene therapy·2026
Same journal

Hyperthermia-Enhanced Adeno-Associated Virus Gene Therapy: Mechanisms, Delivery Technologies, and Translational Potential.

Human gene therapy·2026
Same journal

Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings.

Human gene therapy·2026
See all related articles

Area of Science:

  • Immunology
  • Genetics
  • Biotechnology

Background:

  • Severe combined immunodeficiency disease (SCID) can result from adenosine deaminase (ADA) deficiency.
  • Current treatments for ADA-SCID have limitations.
  • Gene therapy offers a potential alternative for treating genetic disorders.

Purpose of the Study:

  • To evaluate the efficacy of genetically corrected T cells as a treatment for ADA-SCID.
  • To assess the in vivo activity and clinical value of ADA-corrected T cells.

Main Methods:

  • Patients with ADA-SCID received monthly infusions of genetically corrected T cells.
  • Adenosine deaminase (ADA) activity in peripheral blood was measured.
  • In vivo antibody production to blood group antigen was assessed.

Related Experiment Videos

Main Results:

  • Measurable ADA activity was detected in the peripheral blood of treated patients.
  • Successful in vivo production of antibody to blood group antigen was observed.
  • Genetically corrected T cells demonstrated clinical value.

Conclusions:

  • Genetically corrected T cells are a clinically valuable vehicle for gene therapy in ADA-SCID.
  • This approach shows potential for restoring immune function in patients with ADA deficiency.